Sepp-Lorenzino Laura 4
4 · Intellia Therapeutics, Inc. · Filed Jan 6, 2023
Insider Transaction Report
Form 4
Sepp-Lorenzino Laura
EVP, Chief Scientific Officer
Transactions
- Sale
Common Stock
2023-01-05$39.10/sh−689$26,940→ 17,629 total - Sale
Common Stock
2023-01-04$37.21/sh−2,508$93,323→ 19,959 total - Sale
Common Stock
2023-01-05$38.22/sh−1,641$62,719→ 18,318 total
Footnotes (4)
- [F1]Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2023.
- [F2]The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.80 to $38.78, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 5, 2023 at each separate price.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.98 to $39.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 5, 2023 at each separate price.